ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Yale Cancer Center
New Haven, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Yale Cancer Center (5)
2024
-
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103)
Journal of Clinical Pharmacology, Vol. 64, Núm. 5, pp. 544-554
-
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Journal of Clinical Oncology
2023
2019
-
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228